within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DI04_Cefiderocol;

model Cefiderocol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 1.438888888888889e-06,
    adminDuration = 600,
    adminMass = 2000 / 1000000,
    adminCount = 1,
    Vd = 0.018,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0135,
    k12 = 4.611111111111111e-06,
    k21 = 4.611111111111111e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cefiderocol</td></tr><tr><td>ATC code:</td><td>J01DI04</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>2000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>18</td><td>L</td></tr>
    <tr><td>clearance:</td><td>5.18</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cefiderocol is a novel siderophore cephalosporin antibiotic approved for the treatment of serious Gram-negative bacterial infections, including those caused by carbapenem-resistant organisms. It is administered intravenously and is indicated for use in complicated urinary tract infections (cUTI), hospital-acquired bacterial pneumonia (HABP), and ventilator-associated bacterial pneumonia (VABP).</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers following intravenous administration.</p><h4>References</h4><ol><li><p>Zhanel, GG, et al., &amp; Karlowsky, JA (2019). Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. <i>Drugs</i> 79(3) 271–289. DOI:<a href=\"https://doi.org/10.1007/s40265-019-1055-2\">10.1007/s40265-019-1055-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30712199/\">https://pubmed.ncbi.nlm.nih.gov/30712199</a></p></li><li><p>Sanz-Codina, M, et al., &amp; Al Jalali, V (2024). Target-site cefiderocol pharmacokinetics in soft tissues of healthy volunteers. <i>The Journal of antimicrobial chemotherapy</i> 79(12) 3281–3288. DOI:<a href=\"https://doi.org/10.1093/jac/dkae359\">10.1093/jac/dkae359</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39373642/\">https://pubmed.ncbi.nlm.nih.gov/39373642</a></p></li><li><p>Zahr, N, et al., &amp; Funck-Brentano, C (2022). Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients. <i>Pharmaceutics</i> 14(12) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics14122786\">10.3390/pharmaceutics14122786</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36559279/\">https://pubmed.ncbi.nlm.nih.gov/36559279</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01DI04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cefiderocol;
